Boomray Pharmaceuticals
Tracked across 1 events · 6 articles · First seen Sep 22, 2026 · Last active Sep 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Boomray Pharmaceuticals Co., Ltd. announced on September 22, 2026 that it has entered into an exclusive global license agreement with Novartis Pharma AG for an undisclosed preclinical radioligand therapy (RLT) asset. Under the terms, BoomRay…
Impact: Licensor of the preclinical RLT asset; gains up to USD 900 million in upfront and milestone payments plus royalties, validating its discovery platform and improving its funding position.
Sep 22, 2026 · 6 articles
100
Boomray Pharmaceuticals entered license agreement NovartisBoomRay Novartis...
20
BFC Partners advised Boomray Boomray PharmaceuticalsBoomRay Novartis...
ERGEN INTELLIGENCE
Track Boomray Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard